Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)20.00
  • Today's Change-0.20 / -0.99%
  • Shares traded--
  • 1 Year change+19.76%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 16:26 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Dividends in JPY

Historical dividend information is not available for Kyowa Kirin Co Ltd.
Div growth (TTM)9.80%
More ▼

Earnings history & estimates in JPY

On Aug 01, 2024, Kyowa Kirin Co Ltd reported 2nd quarter 2024 earnings of 43.58 per share. This result exceeded the 28.04 expectation of the one analyst covering the company and exceeded last year's 2nd quarter results by 27.05.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate+64.64%
Kyowa Kirin Co Ltd reported annual 2023 earnings of 151.03 per share on Feb 07, 2024.
Average growth rate+8.85%
More ▼

Revenue history & estimates in JPY

-32768 had 2nd quarter 2024 revenues of 127.41m. This bettered the 117.00m estimate of the one analyst covering the company. This was 36.21% above the prior year's 2nd quarter results.
Average growth rate+6.69%
-32768 had revenues for the full year 2023 of 442.23m. This was 11.01% above the prior year's results.
Average growth rate+9.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.